Hasil Pencarian  ::  Simpan CSV :: Kembali

"As healthcare costs rise in the United States, debate is ongoing over how to obtain better value for dollars spent. In this context, the use of cost-effectiveness analysis (CEA) is more compelling than ever. This book, written by the Second Panel on Cost-Effectiveness in Health and Medicine, reviews key concepts and analytic challenges in CEA. The authors endorse the original Panels concept of a reference case and support its recommendation that analysts take a broad societal perspective; in addition, they recommend a healthcare sector perspective for a second reference case, as well as an important new framework, the Impact Inventory, for detailing costs and effects. The revisions draw on advances in the field and include three new chapters that capture research on decision modeling, methods for evidence synthesis, and ethical considerations. The volume also includes two new worked examples (Appendix A and Appendix B) to illustrate ways to implement the authors recommendations."

"This volume provides a lucid presentation of how to use financial information to manage costs. It explains how the financial processes of an organization (planning, budgeting, capital investment analysis, and costs) are interrelated, and interprets these processes in the context of the firm's strategic objectives and long-term goals."

"ABSTRAKLatar Belakang: Hiponatremia ditemukan pada 15-20 admisi rumah sakit. Hiponatremia berhubungan dengan adverse outcome pada pasien gagal jantung. Penggunaan akuaretik dipertimbangkan untuk tatalaksana hiponatremia pada gagal jantung. Adverse outcomes akibat hiponatremia berdampak terhadap pembiayaan, dan merupakan target potensial untuk intervensi. Studi ini bertujuan menilai efektivitas klinis tatalaksana hiponatremia pada gagal jantung serta menganalisis biaya medis antar metode tatalaksana. Metode: Penelitian ini merupakan studi potong lintang pada pasien dengan gagal jantung dekompensasi akut dengan hiponatremia pada Januari 2014 ndash; Mei 2017. Hasil Penelitian: Total subjek 128 pasien, dengan 71 55.5 subjek mendapatkan terapi konvensional ditambah antagonis reseptor AVP. Terdapat perbedaan bermakna p = 0.041 kenaikan natrium median kelompok antagonis reseptor AVP 4 -8 ndash; 26 dan tanpa antagonis reseptor AVP 3 -16 ndash; 16 , dan perbedaan bermakna p < 0.0001 lama masa rawat median 10.50 3-40 hari pada kelompok antagonis reseptor AVP dan 6 3-71 hari pada kelompok tanpa antagonis reseptor AVP . Analisis biaya parsial tidak menunjukkan perbedaan bermakna pada biaya rerata harian antar kedua kelompok. Kesimpulan: Terdapat perbedaan kenaikan kadar natrium darah di hari ketiga pengobatan dan lama masa rawat antar metode tatalaksana hiponatremia pada gagal jantung dekompensasi akut. Tidak terdapat perbedaan biaya bermakna antar metode tatalaksana hiponatremia pada gagal jantung dekompensasi akut.

---

ABSTRACTBackground Hyponatremia is found in 15 20 of hospital admissions and is associated with adverse outcomes in heart failure, where aquaretics may be considered in its management. Adverse outcomes due to hyponatremia affects funding, and is a potential target for intervention to decrease expenses. We aim to evaluate the clinical effectiveness of hyponatremia treatment methods in heart failure and analyze medical costs between them. Method This is a cross sectional study among acute decompensated heart failure patients with hyponatremia in NCCHK from January 2014 until May 2017. Result 128 subjects were analyzed, with 71 55.5 subjects receiving conventional therapy and AVP receptor antagonist and 57 44.5 receiving conventional therapy only. There was a significant difference in sodium increase 4 8 ndash 26 in AVP receptor antagonist patients and 3 16 ndash 16 in those without, p 0.041 , and in length of stay 10.50 3 40 days in AVP receptor antagonist patients and 6 3 71 in those without, p 0.0001 . Cost analysis showed no significant difference in average daily cost. Conclusion There is a significant difference in sodium increase after three days of therapy and in length of stay. There is no significant cost difference with the addition of AVP receptor antagonist."